Abcuro reels in $155M to test antibody's potential in rare muscle disease, setting biotech's 2026 BLA plans
Massachusetts biotech Abcuro has secured $155 million to take its biologic through a potentially registrational trial for a rare muscle-wasting disease and to an anticipated regulatory approval filing in 2026, CEO Alex Martin told Endpoints News.
Abcuro’s oversubscribed financing will bankroll a 76-week Phase II/III trial of the biotech’s monoclonal antibody in patients with inclusion body myositis, or IBM. The placebo-controlled trial, which begun in March, will test two doses of ABC008 that is delivered under the skin every eight weeks, medical chief Jeffrey Wilkins said in an interview.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.